<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jia R</submitter><funding>Science and Technology Projects of Lianyungang (Social Development)</funding><funding>Science and Technology Projects of Lianyungang</funding><funding>Jiangsu Provincial Administration of Traditional Chinese Medicine</funding><funding>National Natural Science Foundation of China</funding><funding>Pioneer Incubator Fund</funding><funding>Lianyungang Science and Technology Program Project</funding><pagination>100</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11969723</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>22(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Chemotherapy-induced peripheral neuropathy (CIPN) is a serious adverse reaction to chemotherapy with limited treatment options. Research has indicated that neutrophil extracellular traps (NETs) are critical for the pathogenesis of CIPN. LPS/HMGB1 serve as important inducers of NETs. Here, we aimed to target the inhibition of NET formation (NETosis) to alleviate CIPN.&lt;h4>Methods&lt;/h4>Oxaliplatin (L-OHP) was used to establish a CIPN model. The mice were pretreated with fucoidan to investigate the therapeutic effect. SR-A1&lt;sup>-/-&lt;/sup> mice were used to examine the role of scavenger receptor A1 (SR-A1) in CIPN. Bone marrow-derived macrophages (BMDMs) isolated from SR-A1&lt;sup>-/-&lt;/sup> mice and WT mice were used to investigate the mechanism by which macrophage phagocytosis of</pubmed_abstract><journal>Journal of neuroinflammation</journal><pubmed_title>Fucoidan reduces NET accumulation and alleviates chemotherapy-induced peripheral neuropathy via the gut-blood-DRG axis.</pubmed_title><pmcid>PMC11969723</pmcid><funding_grant_id>SF2314</funding_grant_id><funding_grant_id>MS2023122</funding_grant_id><funding_grant_id>82271252</funding_grant_id><funding_grant_id>SF2122</funding_grant_id><funding_grant_id>82073910</funding_grant_id><funding_grant_id>GWRX-BR-2024-3</funding_grant_id><funding_grant_id>82204542</funding_grant_id><pubmed_authors>Wan L</pubmed_authors><pubmed_authors>Liu WT</pubmed_authors><pubmed_authors>Zhang M</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Jia R</pubmed_authors><pubmed_authors>Miao C</pubmed_authors><pubmed_authors>Zong L</pubmed_authors><pubmed_authors>Cai Y</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Zhu X</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Hu L</pubmed_authors><pubmed_authors>Jin L</pubmed_authors><pubmed_authors>Tian Q</pubmed_authors><pubmed_authors>Wu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Fucoidan reduces NET accumulation and alleviates chemotherapy-induced peripheral neuropathy via the gut-blood-DRG axis.</name><description>&lt;h4>Background&lt;/h4>Chemotherapy-induced peripheral neuropathy (CIPN) is a serious adverse reaction to chemotherapy with limited treatment options. Research has indicated that neutrophil extracellular traps (NETs) are critical for the pathogenesis of CIPN. LPS/HMGB1 serve as important inducers of NETs. Here, we aimed to target the inhibition of NET formation (NETosis) to alleviate CIPN.&lt;h4>Methods&lt;/h4>Oxaliplatin (L-OHP) was used to establish a CIPN model. The mice were pretreated with fucoidan to investigate the therapeutic effect. SR-A1&lt;sup>-/-&lt;/sup> mice were used to examine the role of scavenger receptor A1 (SR-A1) in CIPN. Bone marrow-derived macrophages (BMDMs) isolated from SR-A1&lt;sup>-/-&lt;/sup> mice and WT mice were used to investigate the mechanism by which macrophage phagocytosis of</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2026-06-02T17:32:58.328Z</modification><creation>2025-07-08T03:13:08.382Z</creation></dates><accession>S-EPMC11969723</accession><cross_references><pubmed>40186245</pubmed><doi>10.1186/s12974-025-03431-5</doi></cross_references></HashMap>